Riskpilot← Back to searchSign inGet full accessKA.SH med AB
ABActiveOrg 5591511596Bäckgatan 12General medical practice activities · NACE 8621Est. 20180 employees
Revenue 2024
SEK 0
EBITDA margin
—
-126% vs 2023
Equity ratio
44.5%
Financial strength
Net profit 2024
SEK -34K
-136% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -30K | -126% |
| Net profit | SEK -34K | -136% |
| Total assets | SEK 43K | -88% |
| Equity | SEK 19K | -89% |
| Employees | 0 | — |
Legal name
KA.SH med AB
Org number
5591511596
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
2 mars 2018
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva konsultverksamhet som allmänmedicinsk läkare, med behandlingsuppdrag inom primärvård och därmed förenlig verksamhet. Bolaget skall även bedriva sin verksamhet kring farmaceutiska produkter. Bolaget skall även producera samt distribuera produkterna i norden och därmed förenlig verksamhet.
Address
Bäckgatan 12
Email
karinsharafi@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 88 | 118 | 1 173 | 142 | 0 |
| Staff expenses | — | — | −0 | −1 | −4 |
| EBITDA | 65 | 81 | 912 | 114 | −30 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 65 | 81 | 912 | 114 | −30 |
| Net financials | — | — | 0 | 3 | −4 |
| Profit before tax | 65 | 81 | 912 | 117 | −34 |
| Tax | −14 | −17 | −188 | −24 | — |
| Net profit | 51 | 64 | 724 | 93 | −34 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 144 | 137 | 1 214 | 372 | 43 |
| Equity | 101 | 116 | 775 | 168 | 19 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 43 | 22 | 439 | 204 | 24 |
| Total debt | 43 | 22 | 439 | 204 | 24 |
EBITDA margin
-2955400.0%
This company
15.8%
Market median
-18705163% vs market
20202024
Equity ratio
44.5%
This company
38.2%
Market median
+16% vs market
20202024
Return on equity
-176.8%
This company
18.4%
Market median
-1061% vs market
20202024
Net profit margin
-3372100.0%
This company
8.1%
Market median
-41630964% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.25×
This company
0.62×
Market median
-102% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KS Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of KA.SH med AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Sharafi | Chief Executive Officer | 0 companies |
| Jamileh Sarrafan | Deputy Board Member | 0 companies |